(Health-NewsWire.Net, August 26, 2016 ) FSH brought in a global sales value of over USD 1.2 billion in 2013 to which Gonal-f (FSH?) made by Merck Serono contributed USD 813 million with a market share of 63% while Puregon (FSH?) of Merck contributed USD 481 million with a market share of 37%. FSH develops fast after entering China, annual sales value rising from less than CNY 2 million in 2006 to CNY 215 million in 2014 and CAGR during this period reaching 84.2%. Merck Serono (rhFSH?), Livzon Pharmaceutical Group Co., Ltd (UFSH), IBSA (UFSH) and Organon (rhFSH?) dominate the Chinese market, among which Livzon Pharmaceutical Group Co., Ltd has the largest market share of about 59% for sales value in 2014.
As the number of patients suffering from infertility is huge in China, FSH has good market prospects. Request sample at : https://marketreportscenter.com/request-sample/133425
Readers can get at least the following information from this report: -market size of FSH in China -competitive landscape of FSH in Chinese market -price of FSH made by different enterprises in China -market outlook of FSH in China
Check for Discount at : https://marketreportscenter.com/request-discount/133425 The author suggests the following groups of people purchase this report: -manufacturers of endocrine regulator -investors/ research institutions interested in Chinese medicine market -any interest in the Chinese medicine market, please contact CRI for customized survey service
Browse full report with TOC : https://marketreportscenter.com/reports/133425/investigation-report-on-china-follicle-stimulating-hormone-fsh-market-2010-2019
Connect for more details: Sam Collins Market Reports Center Call us : 1-646-883-3044 (US) Email : info@marketreportscenter.com visit our website : https://marketreportscenter.com
Market Reports Center
Sam Collins
1-646-883-3044
sam@marketreportscenter.com
Source: EmailWire.Com
|